Patients in Ireland awaiting approval for Skyclarys, a treatment for Friedreich’s ataxia, are calling for greater transparency in the country’s drug reimbursement process. The medication, which targets a rare neurological disorder, has been approved in other European countries but remains under review in Ireland. Advocacy groups highlight concerns over delays and lack of clear communication, affecting patients’ access to essential care.
The current system, which evaluates the cost-effectiveness of new drugs, has come under scrutiny. Critics argue that the process lacks transparency, making it difficult for patients and families to understand the timeline or rationale behind decisions. With Friedreich’s ataxia progressing rapidly, delays in treatment can have serious consequences.
Health officials have not yet announced changes to the process, but growing public and patient pressure may lead to reforms. The situation underscores broader challenges in balancing healthcare costs with patient needs.
The debate reflects a wider discussion on how to improve access to innovative treatments while managing public resources.
